The biotech announced disappointing early stage results for its single-dose COVID-19 vaccine candidate. What happened Shares of Arcturus Therapeutics Holdings (NASDAQ:ARCT) were plunging 53.7% as of 11:16 a.m. EST on Tuesday. The huge decline came after the biotech reported data from an early-stage clinical study of COVID-19 vaccine candidate ARCT-021. So what Investors had...
Read Full StoryTop News
Related
Digital Talkback: David Perdue's brief flirtation with a 2022 Senate run draws reader insights
, 25min
0
'We haven't been good enough': Anas Sarwar pledges to rebuild Scottish Labour as leader – video
, 28min
0